Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 362 entries
Sorted by: Best Match Show Resources per page
Correction to "assessing the dual activity of a chalcone-phthalocyanine conjugate: design, synthesis, and antivascular and photodynamic properties".

Molecular pharmaceutics

Tuncel S, Trivella A, Atilla D, Bennis K, Savoie H, Albrieux F, Delort L, Billard H, Dubois V, Ahsen V, Caldefie-Chézet F, Richard C, Boyle RW, Ducki S, Dumoulin F.
PMID: 25590168
Mol Pharm. 2015 Feb 02;12(2):663. doi: 10.1021/mp5008426. Epub 2015 Jan 15.

No abstract available.

Cite
Tuncel S, Trivella A, Atilla D, et al. Correction to "assessing the dual activity of a chalcone-phthalocyanine conjugate: design, synthesis, and antivascular and photodynamic properties". Mol Pharm. 2015;12(2):663doi: 10.1021/mp5008426.
Tuncel, S., Trivella, A., Atilla, D., Bennis, K., Savoie, H., Albrieux, F., Delort, L., Billard, H., Dubois, V., Ahsen, V., Caldefie-Chézet, F., Richard, C., Boyle, R. W., Ducki, S., & Dumoulin, F. (2015). Correction to "assessing the dual activity of a chalcone-phthalocyanine conjugate: design, synthesis, and antivascular and photodynamic properties". Molecular pharmaceutics, 12(2), 663. https://doi.org/10.1021/mp5008426
Tuncel, Sinem, et al. "Correction to "assessing the dual activity of a chalcone-phthalocyanine conjugate: design, synthesis, and antivascular and photodynamic properties"." Molecular pharmaceutics vol. 12,2 (2015): 663. doi: https://doi.org/10.1021/mp5008426
Tuncel S, Trivella A, Atilla D, Bennis K, Savoie H, Albrieux F, Delort L, Billard H, Dubois V, Ahsen V, Caldefie-Chézet F, Richard C, Boyle RW, Ducki S, Dumoulin F. Correction to "assessing the dual activity of a chalcone-phthalocyanine conjugate: design, synthesis, and antivascular and photodynamic properties". Mol Pharm. 2015 Feb 02;12(2):663. doi: 10.1021/mp5008426. Epub 2015 Jan 15. PMID: 25590168.
Copy Download .nbib Format: NLM
Theranostic nanomedicine with functional nanoarchitecture.

Molecular pharmaceutics

Pan D.
PMID: 23452025
Mol Pharm. 2013 Mar 04;10(3):781-2. doi: 10.1021/mp400044j.

No abstract available.

Cite
Pan D. Theranostic nanomedicine with functional nanoarchitecture. Mol Pharm. 2013;10(3):781-2doi: 10.1021/mp400044j.
Pan, D. (2013). Theranostic nanomedicine with functional nanoarchitecture. Molecular pharmaceutics, 10(3), 781-2. https://doi.org/10.1021/mp400044j
Pan, Dipanjan. "Theranostic nanomedicine with functional nanoarchitecture." Molecular pharmaceutics vol. 10,3 (2013): 781-2. doi: https://doi.org/10.1021/mp400044j
Pan D. Theranostic nanomedicine with functional nanoarchitecture. Mol Pharm. 2013 Mar 04;10(3):781-2. doi: 10.1021/mp400044j. PMID: 23452025.
Copy Download .nbib Format: NLM
Correction to "Factorial Design Based Multivariate Modeling and Optimization of Tunable Bioresponsive Arginine Grafted Poly(cystaminebis(acrylamide)-diaminohexane) Polymeric Matrix Based Nanocarriers".

Molecular pharmaceutics

Yang R, Nam K, Kim SW, Turkson J, Zou Y, Zuo YY, Haware RV, Chougule MB.
PMID: 29470076
Mol Pharm. 2018 Mar 05;15(3):1377. doi: 10.1021/acs.molpharmaceut.8b00130. Epub 2018 Feb 22.

No abstract available.

Cite
Yang R, Nam K, Kim SW, et al. Correction to "Factorial Design Based Multivariate Modeling and Optimization of Tunable Bioresponsive Arginine Grafted Poly(cystaminebis(acrylamide)-diaminohexane) Polymeric Matrix Based Nanocarriers". Mol Pharm. 2018;15(3):1377doi: 10.1021/acs.molpharmaceut.8b00130.
Yang, R., Nam, K., Kim, S. W., Turkson, J., Zou, Y., Zuo, Y. Y., Haware, R. V., & Chougule, M. B. (2018). Correction to "Factorial Design Based Multivariate Modeling and Optimization of Tunable Bioresponsive Arginine Grafted Poly(cystaminebis(acrylamide)-diaminohexane) Polymeric Matrix Based Nanocarriers". Molecular pharmaceutics, 15(3), 1377. https://doi.org/10.1021/acs.molpharmaceut.8b00130
Yang, Rongbing, et al. "Correction to "Factorial Design Based Multivariate Modeling and Optimization of Tunable Bioresponsive Arginine Grafted Poly(cystaminebis(acrylamide)-diaminohexane) Polymeric Matrix Based Nanocarriers"." Molecular pharmaceutics vol. 15,3 (2018): 1377. doi: https://doi.org/10.1021/acs.molpharmaceut.8b00130
Yang R, Nam K, Kim SW, Turkson J, Zou Y, Zuo YY, Haware RV, Chougule MB. Correction to "Factorial Design Based Multivariate Modeling and Optimization of Tunable Bioresponsive Arginine Grafted Poly(cystaminebis(acrylamide)-diaminohexane) Polymeric Matrix Based Nanocarriers". Mol Pharm. 2018 Mar 05;15(3):1377. doi: 10.1021/acs.molpharmaceut.8b00130. Epub 2018 Feb 22. PMID: 29470076.
Copy Download .nbib Format: NLM
Correction for Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy.

Molecular pharmaceutics

Durham PG, Zhang Y, German N, Mortensen N, Dhillon J, Mitchison DA, Fourie PB, Hickey AJ.
PMID: 26394135
Mol Pharm. 2015 Oct 05;12(10):3782. doi: 10.1021/acs.molpharmaceut.5b00673. Epub 2015 Sep 22.

No abstract available.

Cite
Durham PG, Zhang Y, German N, et al. Correction for Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. Mol Pharm. 2015;12(10):3782doi: 10.1021/acs.molpharmaceut.5b00673.
Durham, P. G., Zhang, Y., German, N., Mortensen, N., Dhillon, J., Mitchison, D. A., Fourie, P. B., & Hickey, A. J. (2015). Correction for Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. Molecular pharmaceutics, 12(10), 3782. https://doi.org/10.1021/acs.molpharmaceut.5b00673
Durham, P G, et al. "Correction for Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy." Molecular pharmaceutics vol. 12,10 (2015): 3782. doi: https://doi.org/10.1021/acs.molpharmaceut.5b00673
Durham PG, Zhang Y, German N, Mortensen N, Dhillon J, Mitchison DA, Fourie PB, Hickey AJ. Correction for Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. Mol Pharm. 2015 Oct 05;12(10):3782. doi: 10.1021/acs.molpharmaceut.5b00673. Epub 2015 Sep 22. PMID: 26394135.
Copy Download .nbib Format: NLM
A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus.

Molecular pharmaceutics

Gonzalez-Valdivieso J, Borrego B, Girotti A, Moreno S, Brun A, Bermejo-Martin JF, Arias FJ.
PMID: 32233501
Mol Pharm. 2020 May 04;17(5):1608-1620. doi: 10.1021/acs.molpharmaceut.0c00054. Epub 2020 Apr 10.

This work analyzes the immunogenicity of six genetically engineered constructs based on elastin-like recombinamers (ELRs) fused to the Gn glycoprotein from Rift Valley fever virus (RVFV). Upon transfection, all constructs showed no effect on cell viability. While fusion constructs...

Cite
Gonzalez-Valdivieso J, Borrego B, Girotti A, et al. A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus. Mol Pharm. 2020;17(5):1608-1620doi: 10.1021/acs.molpharmaceut.0c00054.
Gonzalez-Valdivieso, J., Borrego, B., Girotti, A., Moreno, S., Brun, A., Bermejo-Martin, J. F., & Arias, F. J. (2020). A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus. Molecular pharmaceutics, 17(5), 1608-1620. https://doi.org/10.1021/acs.molpharmaceut.0c00054
Gonzalez-Valdivieso, Juan, et al. "A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus." Molecular pharmaceutics vol. 17,5 (2020): 1608-1620. doi: https://doi.org/10.1021/acs.molpharmaceut.0c00054
Gonzalez-Valdivieso J, Borrego B, Girotti A, Moreno S, Brun A, Bermejo-Martin JF, Arias FJ. A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus. Mol Pharm. 2020 May 04;17(5):1608-1620. doi: 10.1021/acs.molpharmaceut.0c00054. Epub 2020 Apr 10. PMID: 32233501.
Copy Download .nbib Format: NLM
Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges.

Molecular pharmaceutics

Li W, Little N, Park J, Foster CA, Chen J, Lu J.
PMID: 34260250
Mol Pharm. 2021 Aug 02;18(8):2889-2905. doi: 10.1021/acs.molpharmaceut.1c00455. Epub 2021 Jul 14.

Even though nanoparticle drug delivery systems (nanoDDSs) have improved antitumor efficacy by delivering more drugs to tumor sites compared to free and unencapsulated therapeutics, achieving satisfactory distribution and penetration of nanoDDSs inside solid tumors, especially in stromal fibrous tumors,...

Cite
Li W, Little N, Park J, et al. Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges. Mol Pharm. 2021;18(8):2889-2905doi: 10.1021/acs.molpharmaceut.1c00455.
Li, W., Little, N., Park, J., Foster, C. A., Chen, J., & Lu, J. (2021). Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges. Molecular pharmaceutics, 18(8), 2889-2905. https://doi.org/10.1021/acs.molpharmaceut.1c00455
Li, Wenpan, et al. "Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges." Molecular pharmaceutics vol. 18,8 (2021): 2889-2905. doi: https://doi.org/10.1021/acs.molpharmaceut.1c00455
Li W, Little N, Park J, Foster CA, Chen J, Lu J. Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges. Mol Pharm. 2021 Aug 02;18(8):2889-2905. doi: 10.1021/acs.molpharmaceut.1c00455. Epub 2021 Jul 14. PMID: 34260250; PMCID: PMC8752044.
Copy Download .nbib Format: NLM
Improved Photodynamic Activity of Phthalocyanine by Adjusting the Chirality of Modified Amino Acids.

Molecular pharmaceutics

Mu X, Wang D, Lu S, Zhou L, Wei S.
PMID: 34927440
Mol Pharm. 2022 Jan 03;19(1):115-123. doi: 10.1021/acs.molpharmaceut.1c00672. Epub 2021 Dec 18.

Herein, four zinc phthalocyanines (ZnPcs) with chiral lysine modification were synthesized. We found that the chirality of lysine and the chiral structure position strongly influence the properties of ZnPcs. Among the four ZnPcs, d-lysine-modified ZnPc through -NH

Cite
Mu X, Wang D, Lu S, et al. Improved Photodynamic Activity of Phthalocyanine by Adjusting the Chirality of Modified Amino Acids. Mol Pharm. 2021;19(1):115-123doi: 10.1021/acs.molpharmaceut.1c00672.
Mu, X., Wang, D., Lu, S., Zhou, L., & Wei, S. (2022). Improved Photodynamic Activity of Phthalocyanine by Adjusting the Chirality of Modified Amino Acids. Molecular pharmaceutics, 19(1), 115-123. https://doi.org/10.1021/acs.molpharmaceut.1c00672
Mu, Xingchen, et al. "Improved Photodynamic Activity of Phthalocyanine by Adjusting the Chirality of Modified Amino Acids." Molecular pharmaceutics vol. 19,1 (2022): 115-123. doi: https://doi.org/10.1021/acs.molpharmaceut.1c00672
Mu X, Wang D, Lu S, Zhou L, Wei S. Improved Photodynamic Activity of Phthalocyanine by Adjusting the Chirality of Modified Amino Acids. Mol Pharm. 2022 Jan 03;19(1):115-123. doi: 10.1021/acs.molpharmaceut.1c00672. Epub 2021 Dec 18. PMID: 34927440.
Copy Download .nbib Format: NLM
Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.

Molecular pharmaceutics

Salehi N, Kuminek G, Al-Gousous J, Sperry DC, Greenwood DE, Waltz NM, Amidon GL, Ziff RM, Amidon GE.
PMID: 34428047
Mol Pharm. 2021 Sep 06;18(9):3326-3341. doi: 10.1021/acs.molpharmaceut.1c00262. Epub 2021 Aug 24.

Orally dosed drugs must dissolve in the gastrointestinal (GI) tract before being absorbed through the epithelial cell membrane.

Cite
Salehi N, Kuminek G, Al-Gousous J, et al. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis. Mol Pharm. 2021;18(9):3326-3341doi: 10.1021/acs.molpharmaceut.1c00262.
Salehi, N., Kuminek, G., Al-Gousous, J., Sperry, D. C., Greenwood, D. E., Waltz, N. M., Amidon, G. L., Ziff, R. M., & Amidon, G. E. (2021). Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis. Molecular pharmaceutics, 18(9), 3326-3341. https://doi.org/10.1021/acs.molpharmaceut.1c00262
Salehi, Niloufar, et al. "Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis." Molecular pharmaceutics vol. 18,9 (2021): 3326-3341. doi: https://doi.org/10.1021/acs.molpharmaceut.1c00262
Salehi N, Kuminek G, Al-Gousous J, Sperry DC, Greenwood DE, Waltz NM, Amidon GL, Ziff RM, Amidon GE. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis. Mol Pharm. 2021 Sep 06;18(9):3326-3341. doi: 10.1021/acs.molpharmaceut.1c00262. Epub 2021 Aug 24. PMID: 34428047.
Copy Download .nbib Format: NLM
Increasing Drug Loading of Weakly Acidic Telmisartan in Amorphous Solid Dispersions through pH Modification during Hot-Melt Extrusion.

Molecular pharmaceutics

Thompson SA, Davis DA, Moon C, Williams RO.
PMID: 34846902
Mol Pharm. 2021 Nov 30; doi: 10.1021/acs.molpharmaceut.1c00805. Epub 2021 Nov 30.

Oral drug therapy requiring large quantities of active pharmaceutical ingredients (APIs) can cause a substantial pill burden, which can increase nonadherence and worsen healthcare outcomes. Maximizing the drug loading of APIs in oral dosage forms is essential to reduce...

Cite
Thompson SA, Davis DA, Moon C, et al. Increasing Drug Loading of Weakly Acidic Telmisartan in Amorphous Solid Dispersions through pH Modification during Hot-Melt Extrusion. Mol Pharm. 2021;doi: 10.1021/acs.molpharmaceut.1c00805.
Thompson, S. A., Davis, D. A., Moon, C., & Williams, R. O. (2021). Increasing Drug Loading of Weakly Acidic Telmisartan in Amorphous Solid Dispersions through pH Modification during Hot-Melt Extrusion. Molecular pharmaceutics, . https://doi.org/10.1021/acs.molpharmaceut.1c00805
Thompson, Stephen A, et al. "Increasing Drug Loading of Weakly Acidic Telmisartan in Amorphous Solid Dispersions through pH Modification during Hot-Melt Extrusion." Molecular pharmaceutics vol. (2021). doi: https://doi.org/10.1021/acs.molpharmaceut.1c00805
Thompson SA, Davis DA, Moon C, Williams RO. Increasing Drug Loading of Weakly Acidic Telmisartan in Amorphous Solid Dispersions through pH Modification during Hot-Melt Extrusion. Mol Pharm. 2021 Nov 30; doi: 10.1021/acs.molpharmaceut.1c00805. Epub 2021 Nov 30. PMID: 34846902.
Copy Download .nbib Format: NLM
Synchronizing .

Molecular pharmaceutics

Abd-Algaleel SA, Metwally AA, Abdel-Bar HM, Kassem DH, Hathout RM.
PMID: 34460250
Mol Pharm. 2021 Oct 04;18(10):3763-3776. doi: 10.1021/acs.molpharmaceut.1c00276. Epub 2021 Aug 30.

Sesamol is a sesame seed constituent with reported activity against many types of cancer. In this work, two types of nanocarriers, solid lipid nanoparticles (SLNs) and polymeric nanoparticles (PNs), were exploited to improve sesamol efficiency against the glioma cancer...

Cite
Abd-Algaleel SA, Metwally AA, Abdel-Bar HM, et al. Synchronizing . Mol Pharm. 2021;18(10):3763-3776doi: 10.1021/acs.molpharmaceut.1c00276.
Abd-Algaleel, S. A., Metwally, A. A., Abdel-Bar, H. M., Kassem, D. H., & Hathout, R. M. (2021). Synchronizing . Molecular pharmaceutics, 18(10), 3763-3776. https://doi.org/10.1021/acs.molpharmaceut.1c00276
Abd-Algaleel, Shaymaa A, et al. "Synchronizing ." Molecular pharmaceutics vol. 18,10 (2021): 3763-3776. doi: https://doi.org/10.1021/acs.molpharmaceut.1c00276
Abd-Algaleel SA, Metwally AA, Abdel-Bar HM, Kassem DH, Hathout RM. Synchronizing . Mol Pharm. 2021 Oct 04;18(10):3763-3776. doi: 10.1021/acs.molpharmaceut.1c00276. Epub 2021 Aug 30. PMID: 34460250.
Copy Download .nbib Format: NLM
Transition from Amorphous Cyclosporin A Nanoparticles to Size-Reduced Stable Nanocrystals in a Poloxamer 407 Solution.

Molecular pharmaceutics

Chen Z, Higashi K, Ueda K, Moribe K.
PMID: 34843257
Mol Pharm. 2021 Nov 29; doi: 10.1021/acs.molpharmaceut.1c00721. Epub 2021 Nov 29.

Amorphous drug nanoparticles usually exhibit low storage stability. A comprehensive understanding of the molecular states and physicochemical properties of the product is indispensable for designing stable formulations. In the present study, an amorphous cyclosporin A (CyA) nanosuspension with a...

Cite
Chen Z, Higashi K, Ueda K, et al. Transition from Amorphous Cyclosporin A Nanoparticles to Size-Reduced Stable Nanocrystals in a Poloxamer 407 Solution. Mol Pharm. 2021;doi: 10.1021/acs.molpharmaceut.1c00721.
Chen, Z., Higashi, K., Ueda, K., & Moribe, K. (2021). Transition from Amorphous Cyclosporin A Nanoparticles to Size-Reduced Stable Nanocrystals in a Poloxamer 407 Solution. Molecular pharmaceutics, . https://doi.org/10.1021/acs.molpharmaceut.1c00721
Chen, Ziqiao, et al. "Transition from Amorphous Cyclosporin A Nanoparticles to Size-Reduced Stable Nanocrystals in a Poloxamer 407 Solution." Molecular pharmaceutics vol. (2021). doi: https://doi.org/10.1021/acs.molpharmaceut.1c00721
Chen Z, Higashi K, Ueda K, Moribe K. Transition from Amorphous Cyclosporin A Nanoparticles to Size-Reduced Stable Nanocrystals in a Poloxamer 407 Solution. Mol Pharm. 2021 Nov 29; doi: 10.1021/acs.molpharmaceut.1c00721. Epub 2021 Nov 29. PMID: 34843257.
Copy Download .nbib Format: NLM
Effect of 'pH' on the Rate of Pyroglutamate Formation in Solution and Lyophilized Solids.

Molecular pharmaceutics

Bersin LM, Patel SM, Topp EM.
PMID: 34232660
Mol Pharm. 2021 Aug 02;18(8):3116-3124. doi: 10.1021/acs.molpharmaceut.1c00338. Epub 2021 Jul 07.

N-terminal glutamate can cyclize to form pyroglutamate (pGlu) in pharmaceutically relevant peptides and proteins. The reaction occurs nonenzymatically during storage for monoclonal antibodies and shows a strong 'pH' dependence in solution, but the solid-state reaction has not been studied...

Cite
Bersin LM, Patel SM, Topp EM. Effect of 'pH' on the Rate of Pyroglutamate Formation in Solution and Lyophilized Solids. Mol Pharm. 2021;18(8):3116-3124doi: 10.1021/acs.molpharmaceut.1c00338.
Bersin, L. M., Patel, S. M., & Topp, E. M. (2021). Effect of 'pH' on the Rate of Pyroglutamate Formation in Solution and Lyophilized Solids. Molecular pharmaceutics, 18(8), 3116-3124. https://doi.org/10.1021/acs.molpharmaceut.1c00338
Bersin, Lia M, et al. "Effect of 'pH' on the Rate of Pyroglutamate Formation in Solution and Lyophilized Solids." Molecular pharmaceutics vol. 18,8 (2021): 3116-3124. doi: https://doi.org/10.1021/acs.molpharmaceut.1c00338
Bersin LM, Patel SM, Topp EM. Effect of 'pH' on the Rate of Pyroglutamate Formation in Solution and Lyophilized Solids. Mol Pharm. 2021 Aug 02;18(8):3116-3124. doi: 10.1021/acs.molpharmaceut.1c00338. Epub 2021 Jul 07. PMID: 34232660.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 362 entries